Ligand Pharmaceuticals Hits New 52-Week High of $314.37

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 314.37 on June 29, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,898 million. Over the past year, Ligand Pharmaceuticals has demonstrated impressive growth, with a remarkable 294.87% increase in stock price compared to the S&P 500's 20.53% performance. The company has reported positive results for the last three consecutive quarters, showcasing a strong operating cash flow of USD 123.57 million and a net profit of USD 36.68 million, which has grown by 157.25%. With a price-to-earnings ratio of 68.00 and a price-to-book ratio of 3.83, Ligand Pharmaceuticals maintains an attractive valuation. The company is also net-debt free, further solidifying its financial stability. Additionally, it boasts high institutional holdings at 100%, indicating strong confidence from sophisticated investors. Overall, Ligand Pharmaceuticals continues to exhibit market-beating performance both in the short and long term.